Liste publications Plateforme recherche translationnelle
Transcription
Liste publications Plateforme recherche translationnelle
Plateforme de recherche translationnelle Centre Léon Bérard Liste des publications : • Equipe Dr COMBARET : Combaret V, Bréjon S, Iacono I, Schleiermacher G, Pierron G, Ribeiro A,Bergeron C, Marabelle A, Puisieux A. Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Pediatr Blood Cancer. 2011 May;56(5):757-61. doi: 10.1002/pbc.22816. Epub 2011 Jan 11. Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, Bown N,Combaret V, Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A, Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit RJ, Pötschger U, Ambros PF. A multilocus technique for risk evaluation of patients with neuroblastoma. Clin Cancer Res. 2011 Feb 15;17(4):792-804. Mazot P, Cazes A, Boutterin MC, Figueiredo A, Raynal V, Combaret V, Hallberg B, Palmer RH, Delattre O, Janoueix-Lerosey I, Vigny M. The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.Oncogene. 2011 Jan 17. Chargui J, Combaret V, Scaglione V, Iacono I, Péri V, Valteau-Couanet D,Dubrel M, Angevin E, Puisieux A, Romagne F, Bergeron C. Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells. J Immunother. 2010 Jul-Aug;33(6):591-8. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J,Pierron G, Mosseri V, Valent A, Auger N, Plantaz D, Rubie H, Valteau-Couanet D, Bourdeaut F, Combaret V, Bergeron C, Michon J, Delattre O. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol. 2010 Jul 1;28(19):3122-30. Epub 2010 Jun 1. Bouzas-Rodriguez J, Cabrera JR, Delloye-Bourgeois C, Ichim G, Delcros JG,Raquin MA, Rousseau R, Combaret V, Bénard J, Tauszig-Delamasure S, Mehlen P. Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis. J Clin Invest. 2010 Mar 1;120(3):850-8. doi:10.1172/JCI41013. Epub 2010 Feb 15. Hoebeeck J, De Wilde B, Michels E, Combaret V, Yigit N, De Smet E, Van Roy N, Stanbridge E, Ru N, Laureys G, De Paepe A, Speleman F, Vandesompele J. Chromosome 3p microsatellite allelotyping in neuroblastoma: a report on the technical hurdles. Cancer Invest. 2009 Oct;27(8):857-68. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, De Bernardi B, Noguera R, Piqueras M, Cañete A, Castel V, JanoueixListe des publications – Laboratoire de recherche translationnelle – Mars 2011 Lerosey I, Delattre O, Schleiermacher G, Michon J, Combaret V, Fischer M, Oberthuer A, Ambros PF, Beiske K, Bénard J, Marques B, Rubie H, Kohler J, Pötschger U, Ladenstein R, Hogarty MD, McGrady P, London WB, Laureys G, Speleman F, Vandesompele J. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 2009 Jul;10(7):663-71. Epub 2009 Jun 8. Delloye-Bourgeois C, Fitamant J, Paradisi A, Cappellen D, Douc-Rasy S, Raquin MA, Stupack D, Nakagawara A, Rousseau R, Combaret V, Puisieux A, Valteau-Couanet D, Bénard J, Bernet A, Mehlen P. Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med. 2009 Apr 13;206(4):833-47. Epub 2009 Apr 6. Combaret V, Hogarty MD, London WB, McGrady P, Iacono I, Brejon S, Swerts K,Noguera R, Gross N, Rousseau R, Puisieux A. Influence of neuroblastoma stage on serum-based detection of MYCN amplification. Pediatr Blood Cancer. 2009 Sep;53(3):329-31. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen J, Couturier J, Peuchmaur M, Valent A, Plantaz D, Rubie H, Valteau-Couanet D, Thomas C, Combaret V, Rousseau R, Eggert A, Michon J, Speleman F, Delattre O. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009 Mar 1;27(7):1026-33. Epub 2009 Jan 26. Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V, Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet S, Amiel J, Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008 Oct 16;455(7215):967-70. Hoebeeck J, Michels E, Pattyn F, Combaret V, Vermeulen J, Yigit N, Hoyoux C, Laureys G, De Paepe A, Speleman F, Vandesompele J. Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett. 2009 Jan 18;273(2):336-46. Epub 2008 Sep 25. Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, Puisieux A. Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol Cancer. 2008 Jun 5;7:50. Vandesompele J, Michels E, De Preter K, Menten B, Schramm A, Eggert A, Ambros PF, Combaret V, Francotte N, Antonacci F, De Paepe A, Laureys G, Speleman F, Van Roy N. Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. Int J Cancer. 2008 Mar 1;122(5):1177-82. Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A,Molenaar JJ, Menten B, Marques B, Stallings RL, Combaret V, Devalck C, De Paepe A, Versteeg R, Eggert A, Laureys G, Van Roy N, Speleman F. ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer. 2007 Dec;46(12):1098-108. Liste des publications – Laboratoire de recherche translationnelle – Mars 2011 Michalowski MB, de Fraipont F, Plantaz D, Michelland S, Combaret V, Favrot MC. Methylation of tumor-suppressor genes in neuroblastoma: The RASSF1A gene is almost always methylated in primary tumors. Pediatr Blood Cancer. 2008 Jan;50(1):29-32. Rousseau R, Combaret V, Yvon E, Schell M, Philip I, Puisieux A, Frappaz D, Philip T, Bergeron C. [Immunotherapy of poor-prognosis neuroblastoma in children:from bench to bedside]. Bull Cancer. 2006 Feb 1;93(2):153-61. Review. Combaret V, Bergeron C, Noguera R, Iacono I, Puisieux A. Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma. J Clin Oncol. 2005 Dec 1;23(34):8919-20; author reply 8920. Krause A, Combaret V, Iacono I, Lacroix B, Compagnon C, Bergeron C, Valsesia-Wittmann S, Leissner P, Mougin B, Puisieux A. Genome-wide analysis of gene expression in neuroblastomas detected by mass screening. Cancer Lett. 2005 Jul 8;225(1):111-20. Epub 2004 Dec 8. Combaret V, Bergeron C, Bréjon S, Iacono I, Perol D, Négrier S, Puisieux A.Protein chip array profiling analysis of sera from neuroblastoma patients. Cancer Lett. 2005 Oct 18;228(1-2):916. Review. De Preter K, Speleman F, Combaret V, Lunec J, Board J, Pearson A, De Paepe A, Van Roy N, Laureys G, Vandesompele J. No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas. J Clin Oncol. 2005 May 1;23(13):3167-8; author reply 3168-70. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, Brinkschmidt C, Christiansen H, Combaret V, Lastowska M, Nicholson J, O'Meara A, Plantaz D, Stallings R, Brichard B, Van den Broecke C, De Bie S, De Paepe A, Laureys G, Speleman F. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol. 2005 Apr 1;23(10):2280-99. Schleiermacher G, Bourdeaut F, Combaret V, Picrron G, Raynal V, Aurias A,Ribeiro A, Janoueix-Lerosey I, Delattre O. Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain. Oncogene. 2005 May 5;24(20):3377-84. Liste des publications – Laboratoire de recherche translationnelle – Mars 2011 • Equipe Dr ALBERTI Gougelet A, Perez J, Pissaloux D,Besse A, Duc A, Decouvelaere AV, Ranchere-Vince D, Blay JY, and Alberti L miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas, Volume 2011 (2011), Article ID 460650, 13 pages Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY, Alberti L. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer. 2010 Oct 14. Ducimetière F, Lurkin A, Ranchère-Vince D, Decouvelaere AV, Isaac S, Claret-Tournier C, Suignard Y, Salameire D, Cellier D, Alberti L, Bringuier PP,Blay JY, RayCoquard I. [Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary results from EMS study in the Rhône-Alpes region]. Bull Cancer. 2010 Jun;97(6):629-41. Cassier P, Pissaloux D, Alberti L, Ray-Coquard I, Blay JY. [Targeted treatment of rare connective tissue tumors and sarcomas]. Bull Cancer. 2010 Jun;97(6):693-700 Gougelet A, Mansuy A, Blay JY, Alberti L, Vermot-Desroches C. Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody. PLoS One. 2009 Nov 30;4 (11) Fayette J, Boyle H, Chabaud S, Favier B, Engel C, Cassier P, Thiesse P, Méeus P, Sunyach MP, Vaz G, Ray-Coquard I, Ranchère D, Decouvelaere AV, Alberti L, Pérol D, Blay JY. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. Anticancer Drugs. 2010 Jan;21(1):113-9. Cassier PA, Dufresne A, Arifi S, El Sayadi H, Ray-Coquard I, Bringuier PP,Scoazec JY, Alberti L, Blay JY. Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib. Curr Gastroenterol Rep. 2008 Dec;10(6):555-61. Review. Cassier PA, Dufresne A, El Sayadi H, Pissaloux D, Alberti L, Decouvelaere AV, Ranchere D, Ray-Coquard I, Blay JY. [Targeted therapy of sarcomas]. Bull Cancer. 2008 Oct;95(10):963-74. Cassier PA, Dufresne A, Arifi S, El Sayadi H, Labidi I, Ray-Coquard I, Tabone S, Méeus P, Ranchère D, Sunyach MP, Decouvelaere AV, Alberti L, Blay JY. Imatinib mesilate for the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother. 2008 May;9(7):1211-22. Review. Tabone-Eglinger S, Subra F, El Sayadi H, Alberti L, Tabone E, Michot JP, Théou-Anton N, Lemoine A, Blay JY, Emile JF. KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. Clin Cancer Res. 2008 Apr 15;14(8):2285-94. Liste des publications – Laboratoire de recherche translationnelle – Mars 2011 Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P. [Imatinib and solid tumours]. Bull Cancer. 2008 Jan;95(1):99-106. Review. Cassier PA, Dufresne A, Fayette J, Alberti L, Ranchere D, Ray-Coquard I, Blay JY. Emerging drugs for the treatment of soft tissue sarcomas. Expert Opin Emerg Drugs. 2007 Mar;12(1):139-53. Review. Fayette J, Coquard IR, Alberti L, Boyle H, Méeus P, Decouvelaere AV, Thiesse P, Sunyach MP, Ranchère D, Blay JY. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol. 2006 Jul;18(4):347-53. Review. 13: Fayette J, Coquard IR, Alberti L, Ranchère D, Boyle H, Blay JY. ET-743: a novel agent with activity in soft tissue sarcomas. Oncologist. 2005 Nov-Dec;10(10):827-32. Review. Blay JY, Le Cesne A, Alberti L, Ray-Coquart I. Targeted cancer therapies.Bull Cancer. 2005 Feb;92 • Equipe Dr WANG En cours de publication Liste des publications – Laboratoire de recherche translationnelle – Mars 2011